Abstract Details
|
Flavia Nelson, MD
(University of Miami, Miller School of Medicine)
PRESENTER |
Dr. Nelson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Brystol Meyer Squib. Dr. Nelson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Nelson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Nelson has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genetech. The institution of Dr. Nelson has received research support from NIH. Dr. Nelson has received research support from Novartis. |
| Carlos A. Perez, MD (University of Texas Health Science Center At Houston) | Dr. Perez has received personal compensation for serving as an employee of Sanofi-Genzyme. |
| No disclosure on file | |
| Muhammad Akhtar | No disclosure on file |
| Jerry S. Wolinsky, MD, FAAN (McGovern Medical School, UTHealth) | Dr. Wolinsky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avotres. Dr. Wolinsky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Brainstorm Cell Therapeutics. Dr. Wolinsky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cleveland Clinic Foundation. Dr. Wolinsky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Wolinsky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inmagene. Dr. Wolinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis/Sandoz. Dr. Wolinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Wolinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Dr. Wolinsky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Alabama Birmingham. Dr. Wolinsky has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Wolinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Wolinsky has received intellectual property interests from a discovery or technology relating to health care. |
| No disclosure on file | |
| Jeffrey A. Wilken, PhD (NAF) | No disclosure on file |
| Joel S. Steinberg, MD | No disclosure on file |